Latest Updates

3/3/2016 - Targeted Therapies
  • Nursing considerations for newer agents:
  • Expanded indications of
    • Everolimus  - NET tumors of GI or lung origin
    • Palbociclib – in combination with fulvestrant for women with ER-positive, HER2-negative

5/7/2015 - Immunotherapy
  • Expansion of approval of VEGFR-2 inhibitor ramucirumab to include for metastatic colorectal cancer

3/8/2015 - Targeted Therapies
  • Patients receiving lenvatinib, a new FDA-approved treatment option for refractory differentiated thyroid cancer, need preventive education on hand–foot syndrome
  • Monitoring for severe diarrhea and cardiac complications is indicated for patients receiving panobinostat, which is the first HDAC inhibitor approved by the FDA for certain patients with relapsed multiple myeloma

2/18/2015 - Targeted Therapies
  • Palbociclib, first-in-class cyclin-dependent kinase 4/6 inhibitor, was approved in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic breast cancer
  • Nurses need to be aware of the potential for treatment-associated alopecia with palbociclib

2/3/2015 - Targeted Therapies
  • The FDA expanded the indication of Burton’s tyrosine kinase inhibitor, ibrutinib, for patients with Waldenström’s Macroglobulinemia
  • Olaparib is a new therapeutic option for patients with germline BRCA-mutated advanced ovarian cancer who have been treated with 3 or more previous lines of chemotherapy
  • New indication for JAK inhibitor ruxolitinib to include the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea

1/28/2015 - Immunotherapy
  • Special nursing implications for patients receiving blinatumomab, the first bispecific CD19-directed CD3 T cell–engager and first single-agent immunotherapy agent approved for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor ALL
  • Patients with melanoma now have more treatment options as another immune checkpoint inhibitor, nivolumab, was approved for use in patients with advanced or unresectable melanoma
  • Approval of VEGFR-2 inhibitor ramucirumab has been expanded beyond gastric and gastroesophageal junction adenocarcinoma to include patients with metastatic non-small-cell lung cancer

11/7/2014 - Immunotherapy
  • New indication for ramucirumab for advanced gastric or gastro-esophageal junction adenocarcinoma

9/30/2014 - Immunotherapy
  • Expert insight on the nursing implications of the FDA approval of the first PD inhibitor, pembrolizumab, for use in patients with advanced or unresectable melanoma who are no longer responding to other drugs

8/14/2014 - Targeted Therapies
  • The FDA approved idelalisib in combination with rituximab to treat patients with relapsed CLL and also granted accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin’s lymphoma
  • The FDA expanded the approved use of ibrutinib to treat patients with CLL who carry a 17p deletion

7/22/2014 - Targeted Therapies
  • New HDAC inhibitor approved for the treatment of an aggressive form of non-Hodgkin’s lymphoma

6/9/2014 - Immunotherapy
  • CTLA4 immune checkpoint inhibitors, such as ipilimumab, can cause a spectrum of autoimmune-related side effects, including diarrhea

5/7/2014 - Targeted Therapies
  • New accelerated FDA approval of ceritinib for the treatment of patients with ALK-positive, metastatic NSCLC with disease progression who are receiving or are intolerant to crizotinib

5/7/2014 - Immunotherapy
  • Providers now have a new treatment option for patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with the approval of ramucirumab

4/24/2014 - Pain

4/18/2014 - Immunotherapy
  • Ofatumumab now approved for first line therapy in patients with CLL

3/19/2014 - Constipation and Diarrhea

12/27/2013 - Immunotherapy
  • Gail Wilkes, MS, RN, RNC, ANP-BC, MS, AOCN, provides a guide to the nursing care of patients receiving the latest immunotherapy agents, which include monoclonal antibodies, the new checkpoint inhibitors, and cancer vaccines.

12/27/2013 - Targeted Therapies
  • Gail Wilkes, RNC, ANP-BC, MS, AOCN, provides a guide to targeted therapies and the science behind different categories of agents so nurses can better anticipate adverse effects and provide more comprehensive patient education.

12/27/2013 - Treatment of Older Adults
  • Diane Cope, PhD, ARNP-BC, AOCNP®, describes clinical considerations for the management of older adults receiving cancer treatment.